company background image
AJ91

DocCheck XTRA:AJ91 Stock Report

Last Price

€15.95

Market Cap

€80.3m

7D

0%

1Y

-37.2%

Updated

15 Aug, 2022

Data

Company Financials
AJ91 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends5/6

AJ91 Stock Overview

DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe.

DocCheck Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DocCheck
Historical stock prices
Current Share Price€15.95
52 Week High€37.40
52 Week Low€14.65
Beta0.54
1 Month Change1.59%
3 Month Change-17.78%
1 Year Change-37.21%
3 Year Change87.65%
5 Year Change72.79%
Change since IPO-42.38%

Recent News & Updates

Mar 03
Returns On Capital Are A Standout For DocCheck (ETR:AJ91)

Returns On Capital Are A Standout For DocCheck (ETR:AJ91)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...

Jan 18
If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too Late

If You Like EPS Growth Then Check Out DocCheck (ETR:AJ91) Before It's Too Late

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

AJ91DE Healthcare ServicesDE Market
7D0%-0.6%0.3%
1Y-37.2%-37.6%-20.0%

Return vs Industry: AJ91 matched the German Healthcare Services industry which returned -36.3% over the past year.

Return vs Market: AJ91 underperformed the German Market which returned -20.4% over the past year.

Price Volatility

Is AJ91's price volatile compared to industry and market?
AJ91 volatility
AJ91 Average Weekly Movement4.5%
Healthcare Services Industry Average Movement5.2%
Market Average Movement5.7%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.8%

Stable Share Price: AJ91 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: AJ91's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a372Frank Antwerpeshttps://www.doccheck.ag

DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding.

DocCheck Fundamentals Summary

How do DocCheck's earnings and revenue compare to its market cap?
AJ91 fundamental statistics
Market Cap€80.29m
Earnings (TTM)€11.40m
Revenue (TTM)€85.92m

7.0x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AJ91 income statement (TTM)
Revenue€85.92m
Cost of Revenue€61.82m
Gross Profit€24.10m
Other Expenses€12.69m
Earnings€11.40m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.27
Gross Margin28.05%
Net Profit Margin13.27%
Debt/Equity Ratio0%

How did AJ91 perform over the long term?

See historical performance and comparison

Dividends

6.3%

Current Dividend Yield

44%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is AJ91 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AJ91?

Other financial metrics that can be useful for relative valuation.

AJ91 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA3.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does AJ91's PE Ratio compare to its peers?

AJ91 PE Ratio vs Peers
The above table shows the PE ratio for AJ91 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.1x
M3V MeVis Medical Solutions
10.4xn/a€57.9m
NXU Nexus
47.2x16.0%€832.4m
COP CompuGroup Medical SE KGaA
32.3x18.0%€2.3b
LIK LIMES Schlosskliniken
18.6xn/a€73.3m
AJ91 DocCheck
7xn/a€80.3m

Price-To-Earnings vs Peers: AJ91 is good value based on its Price-To-Earnings Ratio (7x) compared to the peer average (27.1x).


Price to Earnings Ratio vs Industry

How does AJ91's PE Ratio compare vs other companies in the European Healthcare Services Industry?

Price-To-Earnings vs Industry: AJ91 is good value based on its Price-To-Earnings Ratio (7x) compared to the German Healthcare Services industry average (32.9x)


Price to Earnings Ratio vs Fair Ratio

What is AJ91's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AJ91 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AJ91's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AJ91 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AJ91 (€15.95) is trading below our estimate of fair value (€24.01)

Significantly Below Fair Value: AJ91 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is DocCheck forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.8%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DocCheck has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether DocCheck is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • DocCheck competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has DocCheck performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


41.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AJ91 has a high level of non-cash earnings.

Growing Profit Margin: AJ91's current net profit margins (13.3%) are lower than last year (14.6%).


Past Earnings Growth Analysis

Earnings Trend: AJ91's earnings have grown significantly by 41.2% per year over the past 5 years.

Accelerating Growth: AJ91's earnings growth over the past year (23.9%) is below its 5-year average (41.2% per year).

Earnings vs Industry: AJ91 earnings growth over the past year (23.9%) exceeded the Healthcare Services industry -3.9%.


Return on Equity

High ROE: AJ91's Return on Equity (31%) is considered high.


Discover strong past performing companies

Financial Health

How is DocCheck's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: AJ91's short term assets (€36.3M) exceed its short term liabilities (€12.1M).

Long Term Liabilities: AJ91's short term assets (€36.3M) exceed its long term liabilities (€6.5M).


Debt to Equity History and Analysis

Debt Level: AJ91 is debt free.

Reducing Debt: AJ91 has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.

Debt Coverage: AJ91 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AJ91 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is DocCheck current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


6.27%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: AJ91's dividend (6.27%) is higher than the bottom 25% of dividend payers in the German market (1.46%).

High Dividend: AJ91's dividend (6.27%) is in the top 25% of dividend payers in the German market (4.5%)


Stability and Growth of Payments

Stable Dividend: AJ91's dividend payments have been volatile in the past 10 years.

Growing Dividend: AJ91's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (44.1%), AJ91's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (72.8%), AJ91's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Frank Antwerpes

no data

Tenure

€211,410

Compensation

Dr. Frank Nicolas Antwerpes serves as the Chief Executive Officer at DocCheck Guano AG. He served as the Chief Executive Officer of DocCheck Medizinbedarf und Logistik GmbH. Dr. Antwerpes serves as Preside...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Frank's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AJ91's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: AJ91's board of directors are seasoned and experienced ( 23.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DocCheck AG's employee growth, exchange listings and data sources


Key Information

  • Name: DocCheck AG
  • Ticker: AJ91
  • Exchange: XTRA
  • Founded: NaN
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: €80.290m
  • Shares outstanding: 5.03m
  • Website: https://www.doccheck.ag

Number of Employees


Location

  • DocCheck AG
  • Vogelsanger Str. 66
  • Cologne
  • North Rhine-Westphalia
  • 50823
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.